Latest News and Press Releases
Want to stay updated on the latest news?
-
Alumis completed enrollment of Phase 3 ONWARD clinical program of ESK-001, a next-generation oral TYK2 inhibitor for moderate-to-severe plaque psoriasis
-
Dublin, May 28, 2025 (GLOBE NEWSWIRE) -- The "Vitiligo Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's offering.The...
-
Dublin, May 16, 2025 (GLOBE NEWSWIRE) -- The "Photodynamic Therapy Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's...
-
Vista, CA, May 13, 2025 (GLOBE NEWSWIRE) -- Mindera Health, a leader in precision medicine for dermatological conditions, today announced positive results from the completion of a randomized,...
-
Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight
New York, USA, April 14, 2025 (GLOBE NEWSWIRE) -- Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight The psoriasis pipeline possesses some drugs in...
-
Alumis and Kaken Pharmaceutical collaborate for oral next-generation TYK2 inhibitor ESK-001 in dermatology in Japan
-
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
-
Pune, March 12, 2025 (GLOBE NEWSWIRE) -- Psoriasis Treatment Market Overview: According to SNS Insider, The Psoriasis Treatment Market was worth USD 22.38 billion in 2023, is projected to grow to...
-
ESK-001 demonstrated robust clinical responses and was well tolerated over 52 weeks in a Phase 2 clinical trial, presented in a late-breaker at AAD 2025
-
Alumis to Present Late-Breaker Psoriasis 52-Week Phase 2 Data Data for ESK-001 at AAD, Data from Ongoing Phase 3 in 1Q 2026